BridgeBio's Breakthrough: Oral Drug Succeeds in Dwarfism Study
BridgeBio's oral infigratinib outperforms BioMarin's injectable therapy in boosting growth for kids with achondroplasia, marking a major win in treating the genetic cause of dwarfism.
/ 9 items
#BMRN↓
Oppenheimer Starts Coverage on Spruce Biosciences with Bullish Outlook
Oppenheimer initiates coverage of Spruce Biosciences with an Outperform rating, citing strong FDA signals, accelerated approval potential, and possible acquisition interest from BioMarin.
BioMarin to Acquire Amicus Therapeutics in $4.8 Billion Deal
BioMarin announces $4.8 billion acquisition of Amicus Therapeutics, adding rare disease treatments Galafold and Pombiliti to its portfolio with expected close in Q2 2026.